Novo Nordisk Pharmatech plans to build a $220.83m facility in Denmark for chronic disease medicine production, set to operate in 2027.

Novo Nordisk Pharmatech plans to construct a $220.83m facility in Denmark to meet increased demand for chronic disease medicines. The 1.5bn Danish crowns plant, set to be operational in 2027, will produce raw materials for Novo Nordisk's drugs and create about 50 new jobs. The company, home to popular treatments like Wegovy and Ozempic, has risen to become Europe's most valuable firm by market capitalization.

August 16, 2024
5 Articles